Special Bulletin

For professional and facility providers

February 12, 2024

Hemophilia and Bleeding Disorder Drug Program: New Pharmacy and Drugs Added

Effective March 1, 2024, Alliance Rx Walgreens Pharmacy is being added as an exclusive specialty pharmacy for members in Highmark's Hemophilia and Bleeding Disorder Drug Program. The other two pharmacies in the program are Soleo Health and the Hemophilia Treatment Center of Western Pennsylvania. Option Care Health will no longer be participating in the program effective March 1, 2024.

In addition, the following three drugs will be available through the program on March 1, 2024:

- J7199 Altuviiio
- J7204 Esperoct
- J7212 Sevenfact

For a full list of the drugs included in the program, click **here**.

Managing hemophilia and bleeding disorders is a complex process involving a rigorous and expensive regimen of specialty drugs. The high cost of these drugs can be a key barrier to care for patients with these conditions.

Through the Hemophilia and Bleeding Disorder Drug Program, Highmark is taking action to help members manage the cost of these drugs. To learn more, go **here**.

The following entities serve western and northeastern Pennsylvania and are independent licensees of the Blue Cross Blue Shield Association: Highmark Inc. d/b/a Highmark Blue Cross Blue Shield, Highmark Choice Company, Highmark Health Insurance Company, Highmark Coverage Advantage Inc., Highmark Benefits Group Inc., First Priority Health, First Priority Life or Highmark Senior Health Company.

All references to "Highmark" in this document are references to the Highmark company that is providing the member's health benefits or health benefit administration and/or to one or more of its affiliated Blue companies.

